Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
05 mars 2024 07h30 HE
|
F. Hoffmann-La Roche Ltd
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month three Zilebesiran added to a standard of care...
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
25 févr. 2024 14h00 HE
|
F. Hoffmann-La Roche Ltd
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed...
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
16 févr. 2024 11h24 HE
|
F. Hoffmann-La Roche Ltd
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate...
New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)
01 févr. 2024 01h03 HE
|
F. Hoffmann-La Roche Ltd
Vabysmo sustained robust drying of retinal fluid, often associated with distorted or blurry vision Up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months...
[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft Guidance für 2023 und erzielt trotz stark rückläufigem COVID-19-Umsatz Verkaufswachstum von 1% (CER)
01 févr. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Konzernverkäufe steigen um 1%1 zu konstanten Wechselkursen (CER; -7% in CHF) und gleichen damit Umsatzrückgang bei COVID-19-Produkten und Erosion durch Biosimilars mehr als aus; Guidance für 2023 wird...
[Annonce événementielle au sens de l’art. 53 RC] Roche dépasse les projections et affiche une croissance des ventes de 1 % (TCC) en 2023, malgré un net recul des ventes lié au COVID-19
01 févr. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Le chiffre d’affaires consolidé progresse de 1 %1 à taux de change constants (TCC ; -7 % en CHF), faisant plus que contrebalancer le recul des ventes lié au COVID-19 et l’érosion induite par les...
[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline
01 févr. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Group sales grow by 1%1 at constant exchange rates (CER; -7% in CHF), more than offsetting the decline in COVID-19-related sales and biosimilar erosion, and thereby exceeding 2023 guidanceExcluding...
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
16 janv. 2024 01h00 HE
|
F. Hoffmann-La Roche Ltd
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC...
Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform
29 déc. 2023 16h30 HE
|
F. Hoffmann-La Roche Ltd
The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease...
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
19 déc. 2023 09h40 HE
|
F. Hoffmann-La Roche Ltd
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study...